Unipoint-anchored cascade amplification strategy integrating FUSE probe-activated CRISPR-Cas12a for dual mode osteopontin detection toward osteosarcoma assessment and therapeutic response evaluation
Biosensors and Bioelectronics · 2027-01 · 316 · 119343
DOI: 10.1016/j.bios.2026.119343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors and Bioelectronics, 2027-01. Verfasst von Jie Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Hospital, Tianjin University, Tianjin, 300072, China; Department of Orthopedics, Tianjin Hospital, Tianjin, 300211, China. Hauptthemen laut MEDLINE: Osteopontin, Osteosarcoma, Biosensing Techniques, Bone Neoplasms. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Tianjin Municipal Education Commission.
Abstract (Originalsprache)
Reliable assessment of disease status and therapeutic response in osteosarcoma remains an unmet clinical need. Integrative bioinformatics analysis and protein-level verification in paired clinical specimens prioritized secreted phosphoprotein 1 (SPP1, osteopontin) as a liquid biopsy target associated with osteosarcoma progression and patient survival. On this basis, CRUMP, a CRISPR-Cas12a and FUSE Probe-based dual-mode biosensing platform, was developed for SPP1 quantification. A bifunctional NH2-ZIF-8 probe co-immobilizes the components required for target recognition and Cas12a activation, while MoS2@AuNPs interfaces transduce the resulting signals. Signal amplification is achieved through a unipoint-anchored multisite cascade based on a DNA tetrahedron-HCR architecture, enabling one-to-multiple parallel amplification while balancing stability and sensitivity. A single Cas12a cleavage event simultaneously decreases the electrochemical (EC) signal and increases the fluorescence (FL) signal. These reciprocal changes allow the two readouts to provide an internal consistency check for each measurement. Each channel covers more than five orders of magnitude, with detection limits of 167.7 fg/mL for EC and 331.6 fg/mL for FL. The broad measurement ranges allow most serum samples to be analyzed directly, without the per-sample dilution optimization that ELISA requires, and the complete analysis takes only approximately 85 min. Validation across osteosarcoma cell lines, clinical specimens, and tumor-bearing mouse models provided preliminary evidence for the feasibility of CRUMP in SPP1 quantification and endpoint assessment of chemotherapeutic response. By combining biomarker prioritization, biosensor engineering, and preliminary application testing, this work presents CRUMP as a candidate platform for SPP1-based assessment of osteosarcoma and its therapeutic response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Hospital, Tianjin University, Tianjin, 300072, China; Department of Orthopedics, Tianjin Hospital, Tianjin, 300211, China.
- Department of Orthopedics, Tianjin Hospital, Tianjin, 300211, China.
- The Third Central Clinical College of Tianjin Medical University, Tianjin, 300170, China.
- Tianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, School of Medicine, Nankai University, Tianjin, 300071, China.
- Department of Orthopedics, Tianjin Hospital, Tianjin, 300211, China. Electronic address: zhangjingyu2010@tju.edu.cn.
- Tianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, School of Medicine, Nankai University, Tianjin, 300071, China. Electronic address: yangshuang@nankai.edu.cn.
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Tianjin Municipal Education Commission
- Natural Science Foundation of Tianjin Municipality
- National Key Clinical Specialty Discipline Construction Program of China
Zitieren
APA
Zhao, J., Gao, M., Ding, H., Song, Y., Zhang, Y., Ten, Y., Wang, F., Miao, Z., Zhang, J., Yang, S., & Jiao, J. (2027). Unipoint-anchored cascade amplification strategy integrating FUSE probe-activated CRISPR-Cas12a for dual mode osteopontin detection toward osteosarcoma assessment and therapeutic response evaluation. Biosensors and Bioelectronics, 316, 119343. https://doi.org/10.1016/j.bios.2026.119343
Vancouver
Zhao J, Gao M, Ding H, Song Y, Zhang Y, Ten Y, et al. Unipoint-anchored cascade amplification strategy integrating FUSE probe-activated CRISPR-Cas12a for dual mode osteopontin detection toward osteosarcoma assessment and therapeutic response evaluation. Biosensors and Bioelectronics. 2027;316:119343. doi:10.1016/j.bios.2026.119343
BibTeX
@article{Zhao2027,
author = {Zhao, Jie and Gao, Miaomiao and Ding, Hongmei and Song, Youshen and Zhang, Yantao and Ten, Yuze and Wang, Fei and Miao, Zukang and Zhang, Jingyu and Yang, Shuang and Jiao, Jun},
title = {Unipoint-anchored cascade amplification strategy integrating FUSE probe-activated CRISPR-Cas12a for dual mode osteopontin detection toward osteosarcoma assessment and therapeutic response evaluation},
journal = {Biosensors and Bioelectronics},
year = {2027},
volume = {316},
pages = {119343},
doi = {10.1016/j.bios.2026.119343}
}
EUVIMED